Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Key Points
Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price
Quarter-end position value fell by $5.18 million, reflecting both trading and stock price changes
Post-trade holding: 11,000 shares valued at $297,990
MLYS stake now 0.19% of AUM, placing it outside the fund’s top five holdings
- 10 stocks we like better than Mineralys Therapeutics ›
What happened
According to an SEC filing dated May 15, 2026, Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in the first quarter. The estimated value of the trade was $4.11 million, based on the quarterly average share price. The move left the fund with 11,000 shares, valued at $297,990 at quarter-end. The net position value declined by $5.18 million, reflecting both share sales and price moves.
What else to know
- Velan trimmed its position in Mineralys Therapeutics; the holding now represents 0.19% of its reportable U.S. equity AUM
- Top holdings after the filing:
- NASDAQ: PRAX: $32.47 million (20.3% of AUM)
- NASDAQ: TARA: $14.77 million (9.3% of AUM)
- NASDAQ: STRO: $12.76 million (8.0% of AUM)
- NYSE: EVMN: $10.26 million (6.4% of AUM)
- NASDAQ: MPLT: $10.02 million (6.3% of AUM)
- As of May 14, 2026, Mineralys Therapeutics shares were priced at $27.27, up 80.5% over the past year, outperforming the S&P 500 by 53.18 percentage points
Company Overview
| Metric | Value |
|---|---|
| Market Capitalization | $2.47 billion |
| Price (as of market close 2026-05-26) | $29.98 |
| Net Income (TTM) | ($151.78 million) |
| One-Year Price Change | 87.84% |
Company Snapshot
- Mineralys Therapeutics' lead product candidate is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor for treating uncontrolled or resistant hypertension.
- The company operates a clinical-stage biopharmaceutical model, focusing on the development and potential commercialization of novel therapies for cardiovascular diseases, with no revenue reported as of the latest period.
- The primary target market includes patients with hypertension and associated cardiovascular conditions, particularly those not adequately managed by existing therapies.
Mineralys Therapeutics is a clinical-stage biotechnology company based in Radnor, Pennsylvania, specializing in the development of innovative therapies for hypertension and related cardiovascular diseases. With a focused pipeline led by lorundrostat, the company aims to address significant unmet needs in the treatment of resistant hypertension. Its strategy centers on advancing proprietary, highly selective drug candidates through clinical development to capture market share in the cardiovascular therapeutics sector.
What this transaction means for investors
Last August, Mineralys Therapeutics didn’t turn many heads when it reported that patients taking its lead candidate, lorundrostat, reduced their systolic blood pressure by 16.9 millimeters of mercury after six weeks of treatment. Later, when AstraZeneca (NYSE:AZN) reported less encouraging results from a similar candidate it’s developing, Mineralys stock shot higher.
Lorundrostat is an orally administered aldosterone synthase inhibitor. It’s being developed for uncontrolled hypertension and resistant hypertension. Mineralys also thinks it could play a role in the treatment of hypertension-related conditions such as chronic kidney disease.
The Food and Drug Administration (FDA) is currently reviewing lorundrostat’s first application for the treatment of hypertension in combination with other antihypertensive drugs. The agency is expected to issue an approval decision on or before Dec. 22, 2026.
As a company without any approved products to sell yet, Mineralys lost $39.3 million in the first quarter. With $646 million in cash on its balance at the end of March, it should have no trouble keeping the lights on until after the FDA is finished reviewing lorundrostat’s application.
Should you buy stock in Mineralys Therapeutics right now?
Before you buy stock in Mineralys Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mineralys Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $463,900!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,401!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 31, 2026.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AstraZeneca Plc. The Motley Fool recommends Mineralys Therapeutics. The Motley Fool has a disclosure policy.
Recommended Articles
